Liu et al. - Google Patents
have temporally distinct roles for leukocyte∆ and PI3K γ Leukocyte PI3KLiu et al.
View PDF- Document ID
- 11216055069147327578
- Author
- Liu L
- Puri K
- Penninger J
- Kubes P
External Links
Snippet
Abstract Phosphoinositide 3-kinases (PI3K) have been considered important in leukocyte motility. PI3Kγ, the class IB PI3K, expressed prominently in leukocytes and also in endothelial cells, mediates leukocyte functional responses induced by chemoattractants. To …
- 210000000265 Leukocytes 0 title abstract description 122
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Leukocyte PI3Kγ and PI3Kδ have temporally distinct roles for leukocyte recruitment in vivo | |
| Collins et al. | platelets in inflammatory bowel disease—pathogenetic role and therapeutic implications | |
| Dessein et al. | IgE antibody and resistance to infection. I. Selective suppression of the IgE antibody response in rats diminishes the resistance and the eosinophil response to Trichinella spiralis infection. | |
| JP2806454B2 (en) | Angiogenesis inhibitor | |
| Hocking et al. | Mechanisms of pulmonary edema induced by tumor necrosis factor-alpha. | |
| Mannaioni et al. | Platelets and inflammation: role of platelet-derived growth factor, adhesion molecules and histamine | |
| Randis et al. | Role of PI3Kδ and PI3Kγ in inflammatory arthritis and tissue localization of neutrophils | |
| Rollins | Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease | |
| Venge et al. | Eosinophil activation in allergic disease | |
| Kieseier et al. | Sequential expression of chemokines in experimental autoimmune neuritis | |
| Kroegel et al. | Pulmonary immune cells in health and disease: the eosinophil leucocyte (Part II) | |
| Cain et al. | The Physiologic Basis for Anticytokine Clinical Trials in the Treatment of Sepsis 1 | |
| Shin et al. | Suppression ofL-histidine decarboxylase mRNA expression by methyleugenol | |
| Pinho et al. | Tissue-and stimulus-dependent role of phosphatidylinositol 3-kinase isoforms for neutrophil recruitment induced by chemoattractants in vivo | |
| Casas et al. | Reconstituted high-density lipoprotein reduces LPS-stimulated TNFα | |
| JP2942196B2 (en) | Pharmaceutical composition for treatment and prevention of diseases mediated by interleukin-1 | |
| US7462618B2 (en) | Treatment of inflammatory autoimmune diseases with alpha-adrenergic antagonists and beta-adrenergic agonists | |
| JPH08511805A (en) | Compound | |
| Vieira-de-Abreu et al. | Cross-talk between macrophage migration inhibitory factor and eotaxin in allergic eosinophil activation forms leukotriene C4–synthesizing lipid bodies | |
| Liu et al. | have temporally distinct roles for leukocyte∆ and PI3K γ Leukocyte PI3K | |
| Ogilvie et al. | Short-term effect of cyclophosphamide and azathioprine on selected aspects of the canine blastogenic response | |
| Janssen et al. | Different effects of anesthetics on spontaneous leukocyte rolling in rat skin | |
| Tavares et al. | RANTES: a new prostaglandin dependent endogenous pyrogen in the rat | |
| Netea et al. | Do only circulating pyrogenic cytokines act as mediators in the febrile response? A hypothesis | |
| Venge | Eosinophils |